Jensen Investment Management Inc. Increases Holdings in Zoetis Inc. (NYSE:ZTS)

Jensen Investment Management Inc. boosted its position in Zoetis Inc. (NYSE:ZTS) by 25.2% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,965,541 shares of the company’s stock after purchasing an additional 395,192 shares during the period. Zoetis comprises 2.8% of Jensen Investment Management Inc.’s investment portfolio, making the stock its 16th biggest position. Jensen Investment Management Inc.’s holdings in Zoetis were worth $340,746,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ZTS. Blue Barn Wealth LLC raised its stake in shares of Zoetis by 6.7% during the 2nd quarter. Blue Barn Wealth LLC now owns 1,613 shares of the company’s stock worth $280,000 after buying an additional 101 shares during the last quarter. Arizona State Retirement System raised its position in Zoetis by 0.7% during the second quarter. Arizona State Retirement System now owns 132,738 shares of the company’s stock worth $23,011,000 after acquiring an additional 987 shares during the last quarter. VELA Investment Management LLC acquired a new position in Zoetis during the second quarter worth about $1,546,000. MCF Advisors LLC lifted its holdings in shares of Zoetis by 30.8% in the second quarter. MCF Advisors LLC now owns 659 shares of the company’s stock valued at $114,000 after purchasing an additional 155 shares in the last quarter. Finally, Waverton Investment Management Ltd grew its position in shares of Zoetis by 47.8% in the second quarter. Waverton Investment Management Ltd now owns 306,119 shares of the company’s stock valued at $53,031,000 after purchasing an additional 98,933 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ZTS has been the topic of a number of analyst reports. Stifel Nicolaus reiterated a “buy” rating and set a $200.00 target price on shares of Zoetis in a report on Tuesday, August 27th. BTIG Research increased their price objective on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Argus raised shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Finally, Piper Sandler raised their price target on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $217.11.

Zoetis Trading Up 0.6 %

ZTS stock traded up $1.18 on Friday, hitting $187.77. 152,510 shares of the company were exchanged, compared to its average volume of 2,646,743. The stock has a market capitalization of $85.07 billion, a price-to-earnings ratio of 35.95, a price-to-earnings-growth ratio of 2.87 and a beta of 0.88. The business’s fifty day moving average is $180.90 and its two-hundred day moving average is $174.57. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The business had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.31 billion. During the same period in the prior year, the firm posted $1.41 EPS. The business’s revenue for the quarter was up 8.3% on a year-over-year basis. As a group, research analysts forecast that Zoetis Inc. will post 5.84 earnings per share for the current year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.